443 related articles for article (PubMed ID: 23819994)
21. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy.
Liaw YF
Antivir Ther; 2006; 11(6):669-79. PubMed ID: 17310811
[TBL] [Abstract][Full Text] [Related]
22. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
Chen Y; Li X; Ye B; Yang X; Wu W; Chen B; Pan X; Cao H; Li L
Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152
[TBL] [Abstract][Full Text] [Related]
23. Doubly Spliced RNA of Hepatitis B Virus Suppresses Viral Transcription via TATA-Binding Protein and Induces Stress Granule Assembly.
Tsai KN; Chong CL; Chou YC; Huang CC; Wang YL; Wang SW; Chen ML; Chen CH; Chang C
J Virol; 2015 Nov; 89(22):11406-19. PubMed ID: 26339052
[TBL] [Abstract][Full Text] [Related]
24. [Relationship between core gene mutations of hepatitis B virus and response to alpha interferon therapy in chronic hepatitis B].
Yoo BC; Kim HJ; Do JH; Park SM
Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):381-8. PubMed ID: 12506242
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B core protein as a therapeutic target.
Mak LY; Wong DK; Seto WK; Lai CL; Yuen MF
Expert Opin Ther Targets; 2017 Dec; 21(12):1153-1159. PubMed ID: 29065733
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells.
Wu J; Meng Z; Jiang M; Pei R; Trippler M; Broering R; Bucchi A; Sowa JP; Dittmer U; Yang D; Roggendorf M; Gerken G; Lu M; Schlaak JF
Hepatology; 2009 Apr; 49(4):1132-40. PubMed ID: 19140219
[TBL] [Abstract][Full Text] [Related]
27. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
Akhan SC; Yulugkural Z; Vahaboglu H
Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
[TBL] [Abstract][Full Text] [Related]
28. Molecular biology of the hepatitis B virus for clinicians.
Datta S; Chatterjee S; Veer V; Chakravarty R
J Clin Exp Hepatol; 2012 Dec; 2(4):353-65. PubMed ID: 25755457
[TBL] [Abstract][Full Text] [Related]
29. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients.
Lin LY; Wong VW; Zhou HJ; Chan HY; Gui HL; Guo SM; Wang H; Huang L; Bao SS; Xie Q; Chan HL
J Med Virol; 2010 Sep; 82(9):1494-500. PubMed ID: 20648602
[TBL] [Abstract][Full Text] [Related]
30. RNA interference inhibits hepatitis B virus gene expression and replication in HepG2-N10 cells.
Ren JL; Pan JS; Cheng T; Dong J; Lu YP; Huang SJ; Shi HX; Wang L; Lian YM
Chin J Dig Dis; 2006; 7(4):230-6. PubMed ID: 17054586
[TBL] [Abstract][Full Text] [Related]
31. Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial.
Chung YH; Song BC; Lee GC; Shin JW; Ryu SH; Jung SA; Yoo K; Lee HC; Lee YS; Suh DJ
Eur J Gastroenterol Hepatol; 2003 May; 15(5):489-93. PubMed ID: 12702905
[TBL] [Abstract][Full Text] [Related]
32. Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection.
Protzer U; Seyfried S; Quasdorff M; Sass G; Svorcova M; Webb D; Bohne F; Hösel M; Schirmacher P; Tiegs G
Gastroenterology; 2007 Oct; 133(4):1156-65. PubMed ID: 17919491
[TBL] [Abstract][Full Text] [Related]
33. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
[TBL] [Abstract][Full Text] [Related]
34. Control of cccDNA function in hepatitis B virus infection.
Levrero M; Pollicino T; Petersen J; Belloni L; Raimondo G; Dandri M
J Hepatol; 2009 Sep; 51(3):581-92. PubMed ID: 19616338
[TBL] [Abstract][Full Text] [Related]
35. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
[TBL] [Abstract][Full Text] [Related]
36. IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2
Xu S; Huang J; Xun Z; Li S; Fu Y; Lin N; Wu W; Chen T; Liu C; Ou Q
Microbiol Spectr; 2022 Dec; 10(6):e0155722. PubMed ID: 36314949
[TBL] [Abstract][Full Text] [Related]
37. [The relationship between HBV genotypes and the efficacy of antiviral therapies in hepatitis B e antigen- positive patients].
Zou HB; Zhu LM; Zhao GM; Liang SR; Li J; Lu CZ; Li H
Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):425-7. PubMed ID: 17594806
[TBL] [Abstract][Full Text] [Related]
38. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
[TBL] [Abstract][Full Text] [Related]
39. IL-4 suppresses the expression and the replication of hepatitis B virus in the hepatocellular carcinoma cell line Hep3B.
Lin SJ; Shu PY; Chang C; Ng AK; Hu CP
J Immunol; 2003 Nov; 171(9):4708-16. PubMed ID: 14568946
[TBL] [Abstract][Full Text] [Related]
40. Treatment of chronic hepatitis B: Evolution over two decades.
Yuen MF; Lai CL
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
